Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355591 | 0.82 | TP53 (0.49) | PDE10AMAPTPOLBTP53 | |
| SCHEMBL18356153 | 0.77 | MAPK1 (0.59) | SMN1; SMN2MAPTPOLBMAPK1HTT | |
| SCHEMBL18355803 | 0.76 | GSK3B (0.44) | SMN1; SMN2MAPTHCAR1POLBTP53 | |
| SCHEMBL540987 | 0.74 | MAPK1 (0.56) | SMN1; SMN2HCAR1MAPK1HTT | |
| SCHEMBL18355769 | 0.72 | GRIN1 (0.32) | POLB | |
| SCHEMBL28100984 | 0.72 | MAPT (0.41) | SMN1; SMN2MAPTHCAR1POLBTP53 | |
| SCHEMBL2194913 | 0.66 | HCAR1 (0.50) | SMN1; SMN2DYRK1AMAPTHCAR1POLB | |
| SCHEMBL2195935 | 0.65 | HCAR1 (0.48) | PDE10ASMN1; SMN2DYRK1AMAPTHCAR1 | |
| SCHEMBL28008223 | 0.64 | KMT2A (0.44) | SMN1; SMN2MAPTPOLBTP53MAPK1 | |
| SCHEMBL20637470 | 0.64 | BRD9 (0.45) | DYRK1AMAPTPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | PDE10A 1884/4885PDE2A 1234/4885SMN1; SMN2 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.